DSpace About DSpace Software 日本語
 

GINMU >
01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2013年度 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/2697

Title: Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model.
Other Titles: 直接的レニン阻害薬であるアリスキレンはラットモデルにおいて非アルコール性脂肪肝炎の進行を抑制する
Authors: Aihara, Yosuke
Yoshiji, Hitoshi
Noguchi, Ryuichi
Kaji, Kosuke
Namisaki, Tadashi
Shirai, Yusaku
Douhara, Akitoshi
Moriya, Kei
Kawaratani, Hideto
Fukui, Hiroshi
Keywords: angiotensin-II
hepatocarcinogenesis
liver fibrosis
non-alcoholic
steatohepatitis
renin
Issue Date: Nov-2013
Publisher: Wiley / The Japan Society of Hepatology
Citation: Hepatology research Vol.43 No.11 p.1241-1250
Abstract: AIM: Renin is a rate-limiting enzyme of the renin-angiotensin system (RAS), and several reports have shown that renin plays an important role in several pathological processes. Although RAS is known to play a pivotal role in the progression of non-alcoholic steatohepatitis (NASH), the role of renin is still obscure. The aim of the current study was to examine the effect of the clinically used direct renin inhibitor (DRI), aliskiren, on the progression of NASH in a rat model. METHODS: The effects of DRI on the choline-deficient L-amino acid-defined (CDAA) diet-induced rat NASH model was examined in conjunction with the activated hepatic stellate cells (Ac-HSC) and neovascularization, both of which are known to play important roles in liver fibrosis development and hepatocarcinogenesis, respectively. RESULTS: DRI exerted a marked inhibitory effect against liver fibrosis development and glutathione-S-transferase placental form (GST-P) positive preneoplastic lesions along with suppression of the Ac-HSC and neovascularization in a dose-dependent manner. DRI also inhibited the hepatic expressions of transforming growth factor-beta 1 (TGF-beta 1), angiotensin-II (AT-II) and vascular endothelial growth factor (VEGF). These results indicated that renin played a pivotal role in the liver fibrosis development and hepatocarcinogenesis of NASH. CONCLUSION: Because DRI is already widely used in the clinical practice with safety, this drug may represent a potential new strategy against the progression of NASH in the future.
Description: 博士(医学)・甲612号・平成26年3月17日
URI: http://hdl.handle.net/10564/2697
ISSN: 13866346
Academic Degrees and number: 24601A612
Degree-granting date: 2014-03-17
Degree name: 博士(医学)
Degree-granting institutions: 奈良県立医科大学
Appears in Collections:2013年度

Files in This Item:

File Description SizeFormat
01本文の要旨.pdf本文の要旨260.39 kBAdobe PDFView/Open
02審査要旨.pdf審査要旨404.72 kBAdobe PDFView/Open
03本文.pdf本文5.59 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback